Results For "0"

Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development Blog Post

New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end drug development to optimize delivery timelines, derisk programs, and improve outcomes. RADNOR, PA – SEPTEMBER…

Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug Blog Post

Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times RADNOR, PA…

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells Blog Post

摘要 尽管针对单一肿瘤相关抗原的免疫疗法取得了最新进展，但多发性骨髓瘤患者最终还是会复发。ISB 2001 is a CD3+ T cell engager (TCE) co-targeting BCMA and CD38 designed…

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers Blog Post

Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor cells. The key mechanism of action of TCEs is to crosslink CD3 on T cells…

[ISoP 网络研讨会点播] — 基于生理的药代动力学（PBPK）在模型引导的药物开发（MIDD）中的应用 — 您了解当前监管机构的接受现状吗？ Blog Post

模型引导的药物开发（MIDD）是药物开发流程与监管审评的关键组成部分，It is frequently utilized as part of a Clinical Pharmacology strategy to inform…

A Best Practice Guide to Managing Non-CRF Data Blog Post

Download PDF

Inferring Target Occupancy for Pembrolizumab Blog Post

Pembrolizumab (Pembro), an anti-PD-1 antibody, has been approved for several cancer indications at 200 mg or 2 mg/kg IV every 3 weeks (Q3W). Understanding the percent target receptor occupancy (RO)...

Dynamic Target-Mediated Drug Disposition (TMDD) Blog Post

Abstract Methods: We have developed a novel pharmacokinetic model, termed dynamic TMDD, to mechanistically describe the phenomenon of drug induced changes in target expression and resultant TMDD. The model is based…

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors Blog Post

Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult to measure. ATG-101 is a bispecific antibody that crosslinks tumor-expressed PD-L1 to T-cell-expressed 4-1BB, thereby…

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities Blog Post

Panelists: Adekemi Taylor, PhD, VP, Quantitive Science Services at CertaraJoab Williamson, Director of Clinical Operations, Faron Pharmaceuticals Summary: LI Pharma Focus America – Issue 04 (2024 年 8 月 31 日) features a…